Singapore’s Ministry of Health (MOH) has confirmed that there is sufficient stockpile of Paxlovid, an oral antiviral drug used to treat Covid-19 in adults at risk of progressing to severe disease. However, access to the drug is no longer fully subsidised in primary care settings, as it was during its initial rollout in 2022.
Paxlovid, developed by Pfizer, contains two components: nirmatrelvir, which inhibits the virus’s replication, and ritonavir, which slows the breakdown of nirmatrelvir in the body to maintain therapeutic levels. The oral medication is most effective when taken early — ideally within three to five days of symptom onset — and is taken twice daily for five days.
Login to read more
